Original Article
Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer
N Engl J Med 1992; 326:1745-1751June 25, 1992
- Abstract
- Abstract
Background.
Few studies have evaluated the late effects of adjuvant chemotherapy for breast cancer. Moreover, the relation between the risk of leukemia and the amount of drug given and the interaction of chemotherapy with radiotherapy have not been described in detail.
Methods.
We conducted a case–control study in a cohort of 82,700 women given a diagnosis of breast cancer from 1973 to 1985 in five areas of the United States. Detailed information about therapy was obtained for 90 patients with leukemia and 264 matched controls. The dose of radiation to the active marrow was estimated from individual radiotherapy records (mean dose, 7.5 Gy).
Results.
The risk of acute nonlymphocytic leukemia was significantly increased after regional radiotherapy alone (relative risk, 2.4), alkylating agents alone (relative risk, 10.0), and combined radiation and drug therapy (relative risk, 17.4). Dose-dependent risks were observed after radiotherapy and treatment with melphalan and cyclophosphamide. Melphalan was 10 times more leukemogenic than cyclophosphamide (relative risk, 31.4 vs. 3.1). There was little increase in the risk associated with total cyclophosphamide doses of less than 20,000 mg.
Conclusions.
Although leukemia occurs in few patients with breast cancer, significantly elevated risks were linked to treatments with regional radiation and alkylating agents. Melphalan is a more potent leukemogen than cyclophosphamide or radiotherapy. Low risks were associated with the levels of cyclophosphamide in common use today. Systemic drug therapy combined with radiotherapy that delivers high doses to the marrow appears to enhance the risk of leukemia. (N Engl J Med 1992;326: 1745–51.)
Media in This Article
Table 1
Characteristics of Case Patients with Breast Cancer Who Had Leukemia or Myelodysplastic Syndrome and Their Matched Controls.*Table 2
Risk of Leukemia and Myelodysplastic Syndrome Associated with Alkylating-Agent Therapy and Radiotherapy for Breast Cancer.*Article Activity
- Article
SINCE the mid-1970s adjuvant chemotherapy has been widely used to treat breast cancer with regional lymph-node involvement.1 More recently, systemic drug therapy has been given to women with localized disease, most of whom survive for many years without a recurrence of cancer.2 Patients with breast cancer who are treated with chemotherapy, particularly regimens containing melphalan, are at increased risk of secondary leukemia.3 4 5 However, the risk associated with cyclophosphamide, the primary alkylating agent used today to treat breast cancer, has not been well explored. Moreover, there are few studies describing the dose–response relation of these drugs, their interaction with radiotherapy, and the effects on risk of age at the time of the diagnosis of breast cancer and timing of chemotherapy. Our study examines these questions in patients with breast cancer in five areas of the United States.
Methods
Study Subjects
A case–control study was conducted in a cohort of 82,700 women with invasive breast cancer diagnosed from 1973 to 1985 who were reported to one of five population-based cancer registries (Connecticut, Iowa, and the metropolitan areas of Detroit, Atlanta [1975 to 1985], and Los Angeles). Because secondary leukemia does not develop until at least 1 to 2 years after therapy, only women who survived at least 18 months after the diagnosis of their breast cancer were eligible for study. Newly diagnosed cases of leukemia were identified from registry files. Cases of chronic lymphocytic leukemia, which has not been related to radiation exposure or the use of cytotoxic drugs, were excluded. Death records were searched for patients with breast cancer whose underlying cause of death was severe anemia or another blood disorder. All suspected leukemic conditions were evaluated and reclassified with the use of reports and slides of peripheral-blood samples, bone marrow aspirates, and biopsy specimens. The 90 eligible case patients included 84 with leukemias and 6 with myelodysplastic syndrome. The leukemic conditions were classified as follows: 74 were acute nonlymphocytic leukemia, 3 were acute lymphocytic leukemia, 7 were chronic myelogenous leukemia, 5 were refractory anemia with excess of blasts, and 1 was acute myelofibrosis. The 20 women from Connecticut with leukemic conditions have been described previously.3 For each case patient, three control patients were selected by means of random sampling from the cohort of women with breast cancer, and they were matched to the case patient on the basis of age and year of diagnosis of the initial tumor (exact year, when possible), race or ethnic group, and length of follow-up, which had to be at least as long as the interval between the diagnosis of breast cancer and the onset of the leukemic condition. Three controls each were found for 84 case patients, and 2 controls each were found for the other 6 case patients.
Abstraction of Medical Records
Information about surgery, radiotherapy, chemotherapy, hormonal therapy, and demographic characteristics was abstracted from registry records, hospital charts, and oncology-clinic records. Because chemotherapy for breast cancer is frequently administered directly from physicians' offices, an attempt was made to contact all private physicians associated with the patients' treatment. Information regarding primary treatment was abstracted from the records kept by at least one of the patients' physicians (or clinics) for 90 percent of the case patients and 92 percent of the controls, and for subsequent courses of therapy for 85 percent of the case patients and 89 percent of the controls. For 3 percent each of the case patients and controls, yearly follow-up reports from the individual hospital tumor registries describing details of radiotherapy and chemotherapy were used to confirm the treatment information obtained from the medical records. Treatments given within one year before the diagnosis of leukemia (or an equivalent date for the controls) were considered unlikely to contribute to the development of a second cancer and were excluded from analyses.
Information on the cumulative dose of alkylating agents was available from the patients' medical charts and physicians' records for 85 percent of the women (81 percent of the case patients and 88 percent of the controls) included in the dose–response analyses. For the remaining patients, the doses were estimated on the basis of the duration of therapy (10 percent) or the best estimate of its duration (4 percent) or were imputed from the median dose (1 percent). The effect on the results of the dose-estimation procedure was evaluated by recomputing the risk of leukemia after patients with incomplete dose information were excluded and after lower-quality dose estimates were increased and then decreased by 30 percent. The results were not materially changed with the use of either method.
Radiation-treatment records were photocopied and used to calculate the individual doses of radiation to 16 sections of active bone marrow as previously described.6 Radiotherapy was primarily administered by megavoltage linear accelerators (48 percent) or cobalt-60 units (48 percent). Typical treatments delivered an average dose to the tumor of 38 Gy from the supraclavicular lymph-node field, as well as 45 Gy from the tangential fields and 40 Gy from the mediastinal field (or chest field) alone or in combination, with an optional boost of 13 Gy to the axilla.
Statistical Analysis
Estimates of the relative risk of leukemia associated with specific treatments were calculated by comparing the case patients' history of exposure with that of their individually matched controls with conditional logistic-regression methods.7 , 8 Comparisons between treatment groups were based on likelihood-ratio tests. Two-sided P values and 95 percent confidence intervals were computed. Estimates of the risk associated with specific alkylating agents were restricted to patients who received the therapy for more than one month and were adjusted for radiotherapy with the use of a categorical variable (yes or no). The relation between the risk of leukemia and the dose of an individual alkylating agent was evaluated by grouping the cumulative dose into evenly spaced categories and computing relative risks between each category and the reference group of patients who had not been exposed to the treatment. These analyses were adjusted for the dose of radiation with a continuous variable. Continuous variables were used to adjust the radiation dose–response analyses for the cumulative dose of melphalan and cyclophosphamide and for the months of treatment with other alkylating agents. Tests of trend were made by assigning the midpoint of the dose group as the representative score. When the number of subjects was so small that the conditions required for convergence of the conditional logistic model were not met, the relative risks were computed with an unmatched logistic model.
The excess risk (the excess number of cases of leukemia per 10,000 patients) within the first 10 years after the diagnosis of breast cancer was estimated by multiplying the relative risk minus 1 by the expected number of leukemias per year, as calculated in our previous study3 of patients with breast cancer treated with chemotherapy (0.56 case of acute nonlymphocytic leukemia expected per 10,000 women-years at risk), and then by 8.5, which is the number of years at risk (assuming a latent period of 1.5 years before the onset of leukemia). For example, a twofold relative risk of leukemia associated with cyclophosphamide therapy would correspond to an excess of 4.76 leukemias per 10,000 patients over a 10-year period: (2 - 1) × 0.56 × 8.5.
Results
Most of the women in our study were over 50 years of age when breast cancer was diagnosed and were treated during the mid-to-late 1970s (Table 1Table 1
Characteristics of Case Patients with Breast Cancer Who Had Leukemia or Myelodysplastic Syndrome and Their Matched Controls.*). The mean length of time between the initial diagnosis of breast cancer and the development of leukemia was 5 years (range, 1.7 to 12.5). Case patients were more likely than controls to have regional node involvement (67 percent vs. 35 percent). More than twice as many case patients as controls were treated with chemotherapeutic regimens that included an alkylating agent (53 percent vs. 19 percent). High-dose regional radiotherapy was given to 42 percent of the case patients and 27 percent of the controls. All but four patients had surgery after the initial diagnosis.There were significant relative risks of leukemia and myelodysplastic syndrome associated with the use of alkylating agents (relative risk, 6.5) and radiotherapy (relative risk, 1.8) (Table 2Table 2
Risk of Leukemia and Myelodysplastic Syndrome Associated with Alkylating-Agent Therapy and Radiotherapy for Breast Cancer.*). The numbers of excess leukemias after drug therapy were concentrated in the subgroups of patients with acute nonlymphocytic leukemia and myelodysplastic syndrome (relative risk, 8.7), and the risk of erythroleukemia, a subtype of acute nonlymphocytic leukemia, was substantially increased (14 cases; relative risk, 21.4). The use of alkylating agents was not linked to increases in chronic myelogenous leukemia or acute lymphocytic leukemia; in fact none of the 10 case patients with these types of leukemia had been treated with chemotherapy. All subsequent analyses included only cases of acute nonlymphocytic leukemia and myelodysplastic syndrome, referred to as "leukemia" for simplicity of presentation.Treatment with radiotherapy alone, alkylating agents alone, or alkylating agents in combination with radiotherapy was linked to a significantly increased risk of leukemia (Table 3Table 3
Relation of Radiation and Alkylating Agents to the Risk of Acute Nonlymphocytic Leukemia and Myelodysplastic Syndrome.*). Patients receiving both systemic drug therapy and radiation were at greatest risk (relative risk, 17.4). Treatment with alkylating agents alone or in combination with radiotherapy resulted in significantly higher risks of leukemia than radiotherapy alone (P = 0.001 and P<0.001, respectively). Patients treated with chemotherapy and radiation did not have a significantly different risk from those given alkylating agents alone in an analysis classifying patients as exposed or unexposed to these agents (P = 0.24). However, in a multivariate model that took into account the type and amount of alkylating agents received and the dose of radiation, the risk associated with combined alkylating-agent therapy and radiotherapy was significantly higher than that for alkylating agents alone (P = 0.02).Patients treated with chemotherapy most often received regimens that included cyclophosphamide alone (30 percent of case patients and 74 percent of controls) or melphalan alone (50 percent of case patients and 19 percent of controls) (Table 4Table 4
Risk of Acute Nonlymphocytic Leukemia and Myelodysplastic Syndrome, According to the Type of Alkylating Agent Administered.*). Cyclophosphamide was usually given in combination with methotrexate and fluorouracil. Melphalan was most often administered as a single agent or less commonly in combination with fluorouracil. The risk of leukemia after treatment with cyclophosphamide alone (no other alkylating agent) was significantly increased (relative risk, 3.1), but was substantially lower than that with melphalan alone (relative risk, 31.4). The difference in the leukemogenic effect between the two drugs was significant (P<0.001). Too few patients received other alkylating agents alone (thiotepa or chlorambucil) to estimate their risks separately. Patients treated with more than one alkylating agent generally received long-term therapy and had a risk of leukemia comparable to that of women given melphalan alone (relative risk, 30.5); six of the seven case patients in this group received melphalan during at least one course of treatment.Table 5Table 5
Risk of Acute Nonlymphocytic Leukemia and Myelodysplastic Syndrome, According to the Estimated Dose of Alkylating Agents and the Duration of Treatment.* presents the risk of leukemia according to the estimated cumulative dose and the duration of cyclophosphamide and melphalan therapy when each was used as the sole alkylating agent. The doses of cyclophosphamide were generally higher for case patients (median dose, 22,300 mg; range, 5700 to 54,800) than for controls (median dose, 16,700 mg; range, 1800 to 55,100), and the risk was found to increase significantly over categories of cumulative dose. The risk among patients treated with doses of more than 20,000 mg was 5.7 times that of women not treated with alkylating agents (95 percent confidence interval, 1.6 to 20.6). The duration of therapy was also strongly associated with the risk of leukemia. Patients who received cyclophosphamide for less than 12 months had little detectable increase in the incidence of leukemia. The risk rose substantially with treatments that lasted longer than 12 months. Women treated for 18 months or more had a sevenfold increased risk of leukemia.Case patients also received higher cumulative doses of melphalan (median dose, 530 mg; range, 230 to 1040) than controls (median dose, 300 mg; range, 80 to 420). There was evidence of a steeply graded dose–response curve, with risks climbing to 133-fold for doses of more than 350 mg (data not shown). The duration of treatment with melphalan was directly related to the risk of leukemia, especially in patients treated for 15 months or more. Three controls and no case patients received melphalan for less than 12 months. Analyses of cyclophosphamide and melphalan treatment with other dose groupings and after adjustment for the stage of breast cancer yielded similar results.
The cumulative dose, duration of treatment, and intensity (average dose per month) of alkylating-agent therapy were evaluated separately and jointly. The cumulative dose appeared to be the strongest determinant of risk; however, the dose and the duration of chemotherapy were strongly correlated in these data. The intensity of the dose did not appear to influence the risk of leukemia in a model accounting for cumulative dose.
Women treated with regional radiotherapy received a mean dose of 7.5 Gy averaged over the total active bone marrow (median dose, 7.2 Gy). There was a significant trend in the risk of leukemia with increasing doses of radiation, after adjustment for the effects of alkylating agents (Table 6Table 6
Risk of Acute Nonlymphocytic Leukemia and Myelodysplastic Syndrome, According to the Dose of Radiation to the Total Active Bone Marrow.*). Patients receiving doses of 9.0 Gy or more were subject to a sevenfold elevated risk. A similar dose–response pattern was found when analyses were restricted to radiotherapy given within the first 12 months after the initial diagnosis. The risk of leukemia was especially increased among the six case patients and four controls given radiation as both initial and subsequent therapy (relative risk, 15.5; 95 percent confidence interval, 2.6 to 92). Excluding patients treated with alkylating agents from the analysis lowered the overall risk due to radiation somewhat (relative risk, 1.9; 95 percent confidence interval, 0.7 to 5.0); however, a significantly increased risk persisted among women who were treated with radiotherapy alone and exposed to more than 9 Gy (relative risk, 10.4).The risk of leukemia that was associated with alkylating-agent therapy was lower among women in whom breast cancer was diagnosed before the age of 50 years (relative risk, 2.4) than among women who were at least 50 at the time of diagnosis (relative risks, 13.0, 15.0, and 10.5, for age groups 50 to 59, 60 to 69, and ≥70 years, respectively), but this difference was not significant (P = 0.49 by the test of homogeneity). The patterns of risk according to age were similar after melphalan and cyclophosphamide therapy. Because of the concentration of patients treated with melphalan during the mid-1970s, women given a diagnosis of breast cancer from 1975 to 1976 had an exceptionally high risk of leukemia. A threefold increase in the risk was evident during the later calendar years (1979 and after) when practically all patients treated with alkylating agents received cyclophosphamide-based regimens. An excess number of leukemias linked to treatment with alkylating agents was observed for patients from each cancer registry.
The pattern of the risk of leukemia according to the length of time since the first treatment with alkylating agents is shown in Table 7Table 7
Risk of Leukemia and Myelodysplastic Syndrome, According to the Time since the First Treatment with Alkylating Agents.. The influence of continued exposure with subsequent courses of chemotherapy was minimized by the exclusion from these analyses of women who received multiple courses of chemotherapy or alkylating agents for more than 30 months. The risk of leukemia was elevated throughout most intervals, but was most prominent within two to seven years after the initiation of therapy. The risk appeared to approach normal levels after seven years (relative risk, 1.8). Women who had received the last drug treatment within two years of the diagnosis of leukemia (or an equivalent date for controls) had an immediate high risk (relative risk, 18.1; 95 percent confidence interval, 6.4 to 51) (data not shown). Patients in this group tended to receive chemotherapy for longer periods and were primarily treated with melphalan. The risk remained elevated for at least five years after the last drug treatment, and declined thereafter.Alkylating agents were administered as a subsequent course of treatment for 14 case patients and 5 controls. There was little difference in the risk between patients receiving subsequent therapy but no initial therapy (relative risk, 9.6) and those given initial therapy only (relative risk, 7.4). The risk was highest among women who had received alkylating agents for both primary and subsequent courses of therapy (relative risk, 25.7).
No increase in risk was associated with treatment with fluorouracil (67 patients), methotrexate (58 patients), prednisone (20 patients), doxorubicin (13 patients), or vincristine (13 patients) after an adjustment for the effects of alkylating agents and radiation; however, few patients received these drugs in the absence of alkylating agents.
Discussion
We studied patients with breast cancer treated in the general community during the 1970s and early 1980s, a period when adjuvant chemotherapy was introduced and later came into wide use. Women treated with alkylating agents had an eightfold increase in the risk of acute nonlymphocytic leukemia and myelodysplastic syndrome. The risk was significantly increased within three years after the initial treatment with chemotherapy. Melphalan therapy accounted for most of this excess risk, with the relative risk increasing 30-fold. Cyclophosphamide was less leukemogenic, with a more moderate threefold increase in the risk. The risks were especially heightened among women treated with multiple alkylating agents during several courses of treatment and with alkylating agents administered in combination with high-dose regional radiotherapy.
In interpreting these results, consideration should be given to changes in breast-cancer therapy over the past decade. Melphalan is rarely used today for adjuvant therapy, cyclophosphamide is given at lower doses and for shorter periods than in the past, and the use of adjuvant radiotherapy after mastectomy has largely been replaced by conservative surgery with localized radiotherapy. However, because women in the study received therapy over a wide range of doses, we were able to provide estimates of risk at the lower dose levels currently used to treat patients with breast cancer. The relation between dose and effect found in this study may also be applicable to other therapeutic settings.
There are few quantitative data on the ability of cyclophosphamide to induce leukemia at the lower doses currently used for adjuvant therapy. In our study we observed a significant trend of increasing risk with increasing doses of cyclophosphamide. The risk of leukemia was especially high among women who received cumulative doses exceeding 20,000 mg. These results are consistent with those of a previous study of breast cancer5 and studies of ovarian cancer9 , 10 that found elevated risks at higher doses. Data from clinical trials of breast cancer have not revealed an excess incidence of leukemia after adjuvant chemotherapy including cyclophosphamide, probably because the small numbers of patients involved were not sufficient to detect small risks of leukemia at the low doses administered.11 12 13 In our study, with a source, population of more than 82,000 women with breast cancer, we were able to confirm that low risks of leukemia (e.g., approximately twofold) are associated with treatment with cyclophosphamide at levels currently used in adjuvant therapy. Iatrogenic leukemia, however, is a rare occurrence after breast cancer, and only about 5 of 10,000 patients treated for 6 months with a cyclophosphamide-based adjuvant regimen might be expected to have leukemia within 10 years of the diagnosis of breast cancer.
Melphalan given as primary therapy for ovarian cancer and multiple myeloma has been reported to have a much higher leukemogenic potential than cyclophosphamide.9 , 10 , 14 The present study confirmed these findings among patients with breast cancer who were receiving adjuvant therapy and estimated that there was a 10-fold difference in risk between melphalan and cyclophosphamide. When melphalan was used as the sole alkylating agent, there was a steep gradient in risk with increasing cumulative dose. The risk for doses exceeding 350 mg was more than 100-fold. The magnitude of the overall risk associated with melphalan was similar to that found among patients with breast cancer who were enrolled in clinical trials.4 Fisher et al. found no relation to the dose,4 however, probably because there was strict uniformity of treatment in the randomized trials.
An important finding of the current study is that radiotherapy that delivers high doses to bone marrow in the chest wall and other areas may add appreciably to the risk of leukemia after chemotherapy in a manner that is consistent with a multiplicative relation. Patients with breast cancer who were treated with radiotherapy and alkylating agents were found to have a significantly higher risk than women receiving alkylating agents alone. The literature is conflicting regarding the risk after combined therapy. Two recent investigations of Hodgkin's disease15 , 16 concluded that the increased risk after chemotherapy is not affected by concomitant radiotherapy; however, other studies have reported the opposite result,17 and considerable uncertainty surrounds this issue.18 Previous evaluations of patients with ovarian cancer have consistently reported that combined treatment with chemotherapy and radiation is not associated with a greater risk of leukemia than treatment with chemotherapy alone.9 , 10 Our study is unique in having substantial numbers of patients with leukemia in each treatment category, coupled with a large comparison group of women who received neither radiation nor chemotherapy; thus, we were able to estimate the separate and combined effects of regional radiotherapy and chemotherapy.
After adjusting for the effects of alkylating agents, we found a twofold increase in the risk of acute leukemia after regional radiotherapy. We found strong evidence of increasing risk with an increasing dose of radiation. A sevenfold increase in risk was associated with average bone marrow doses of more than 9 Gy. The small effect at low doses of radiation was of interest, since current treatment practices involving localized radiation to the breast after conservative surgery deliver substantially lower doses to the bone marrow. Our earlier, but smaller, study of patients with breast cancer in Connecticut who were treated between 1935 and 1972 found no evidence of an excess number of leukemias occurring after radiotherapy19; however, increased risks have been reported among patients with breast cancer treated with radiation who were enrolled in clinical trials.4 , 20 Aside from the effects of chance, changes in the type and techniques of radiotherapy over time may account for some of these differences, since earlier treatments used lower-voltage machines and delivered doses to the active marrow that were about 25 percent lower. Radiotherapy has also been found to cause a twofold increase in the relative risk of leukemia in a large study of patients with cervical cancer,21 although there was no evidence of a marked increase in risk at the highest doses of radiation.
By matching controls with case patients, the study design incorporated an adjustment for age and calendar year at the initial diagnosis and for the time to the onset of leukemia. Although the risk associated with alkylating agents was lower among women who were younger than 50 years of age than among those who were at least 50, this difference was not significant. Previous studies of patients with breast cancer found that the risk of leukemic conditions after melphalan therapy did not vary with age,4 but higher risks have been reported among younger women treated with cyclophosphamide.5
The temporal pattern of drug-induced leukemia is of considerable interest, in particular the level of risk remaining several years after the initial treatment. Among patients treated with a single course of chemotherapy, the risk of leukemia rose rapidly within two years after the initiation of therapy and then appeared to decrease after seven years. Few patients were followed for more than 10 years. A high risk was seen among women who were current or recent users of alkylating agents (<2 years), with a decline seen thereafter. These results indicate that drug-induced leukemia is an early effect, with an elevated risk appearing soon after exposure, and that the excess risk decreases to low levels after 7 to 10 years.
No cases of chronic myelogenous leukemia or acute lymphocytic leukemia in this study had been treated with alkylating agents, and the risk for these subtypes appeared to be substantially lower than the risk for acute nonlymphocytic leukemia and myelodysplastic syndrome. These findings suggest that there may be differences in the mechanisms of carcinogenesis between exposure to cytotoxic therapy and radiation, since studies of atomic-bomb survivors and other groups exposed to radiation indicate that there is a substantial excess of all subtypes of leukemia except chronic lymphocytic leukemia.22 The high risk of erythroleukemia after therapy with alkylating agents appears to be a distinguishing feature of drug-induced leukemia and contrasts with results from practically all radiation studies, except those involving thorium dioxide (Thorotrast). This agent is an alpha-particle emitter that irradiates the marrow throughout life and causes a high number of erythroleukemias.23
Adjuvant chemotherapy for breast cancer is now a well-established treatment of proved effectiveness. The risk of leukemia after cyclophosphamide-based therapy administered according to regimens in common use today is small and unlikely to be a factor in most treatment decisions. On the other hand, the possibility that radiation in combination with alkylating agents greatly enhances the leukemic potential of the treatment is an important source of concern that deserves further study.
We are indebted to all collaborating investigators and staff from participating hospitals and cancer registries — the Georgia Center for Cancer Statistics, the Connecticut Tumor Registry, the Michigan Cancer Foundation, the State Health Registry of Iowa, and the Los Angeles County Cancer Surveillance Program —who provided access to patients' medical charts; to the many physicians who willingly allowed access to their private treatment records; to Elizabeth Dickson, Nancy Holt, Judith Anderson, Helen Gregory, and the abstracting teams from Connecticut and Detroit for support in data collection; to Diane Fuchs from Westat, Inc., for directing the field studies; to Bonnie Johnson for abstracting the chemotherapy-dose data; and to Allison Garman and George Geise from Information Management Services for computing support.
Source Information
From the Radiation Epidemiology Branch, Epidemiology and Biostatistics Program (R.E.C., J.D.B.), and the Environmental Epidemiology Branch (R.N.H.), National Cancer Institute, Bethesda, Md.; the Department of Radiation Physics, University of Texas, M.D. Anderson Cancer Center, Houston (M.S.); the University of Southern California School of Medicine, Los Angeles (L.B.); Emory University School of Public Health, Atlanta (R.S.G.); the Connecticut Tumor Registry, Department of Health Services, Hartford (J.T.F.); the Michigan Cancer Foundation, Detroit (A.G.S.); the State Health Registry of Iowa, Iowa City (P.W.); and Harvard Medical School, Boston (W.C.M.). Address reprint requests to Ms. Curtis at Executive Plaza North, Suite 408, National Cancer Institute, Bethesda, MD 20892.
- References
References
1
Henderson IC Adjuvant systemic therapy of early breast cancer. In: Harris JR. Hellman S, Henderson IC, Kinne DW, eds. Breast diseases. Philadelphia: J.B. Lippincott, 1987:324–53.
2
Mansour
Full Text | Web of Science | Medline3
Curtis
Web of Science | Medline4
Fisher
Web of Science | Medline5
Haas
CrossRef | Web of Science | Medline6
Stovall
CrossRef | Web of Science | Medline7
Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case–control studies. Lyon, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
8
Lubin
CrossRef | Medline9
Greene
Web of Science | Medline10
Kaldor
Full Text | Web of Science | Medline11
Valagussa
Web of Science | Medline12
Holdener
Medline13
Herring
CrossRef | Web of Science | Medline14
Cuzick
CrossRef | Web of Science | Medline15
Tucker
Full Text | Web of Science | Medline16
Kaldor
Full Text | Web of Science | Medline17
Valagussa
Web of Science | Medline18
Blayney
Full Text | Web of Science | Medline19
Curtis
Web of Science | Medline20
Andersson
CrossRef | Web of Science | Medline21
Boice
Web of Science | Medline22
Committee on the Biological Effects of Ionizing Radiations. Health effects of exposure to low levels of ionizing radiation: BEIR V. Washington, D.C.: National Academy Press, 1990.
23
van Kaick G, Wesch H, Lührs H, Liebermann D, Kaul A, Muth H. The German Thorotrast Study — report on 20 years follow-up. In: Taylor DM, Mays CW, Gerber GB, Thomas RG, eds. Risks from radium and thorotrast: BIR report no. 21. London: British Institute of Radiology, 1989:98–104.
- Citing Articles (101)
Citing Articles
1
L. B. Travis, A. K. Ng, J. M. Allan, C.-H. Pui, A. R. Kennedy, X. G. Xu, J. A. Purdy, K. Applegate, J. Yahalom, L. S. Constine, E. S. Gilbert, J. D. Boice. (2012) Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. JNCI Journal of the National Cancer Institute
CrossRef2
Jacob Maddams, D. Maxwell Parkin, Sarah C. Darby. (2011) The cancer burden in the United Kingdom in 2007 due to radiotherapy. International Journal of Cancer 129:12, 2885-2893
CrossRef3
Yukiko NITTA, Toshihiko IKEYA, Akihiro SAKAKIBARA, Yasushi TOMITA. (2011) Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma. The Journal of Dermatology 38:2, 164-168
CrossRef4
Henry G Kaplan, Judith A Malmgren, Mary K Atwood. (2011) Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC Cancer 11:1, 260
CrossRef5
Farshid Dayyani, Hagop Kantarjian, Susan O'Brien, Sherry Pierce, Dan Jones, Stefan Faderl, Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi. (2011) Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 117:1, 110-115
CrossRef6
Wei Zhang, Aldo Becciolini, Annibale Biggeri, Paolo Pacini, Colin R Muirhead. (2011) Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy. Breast Cancer Research 13:2, R38
CrossRef7
Andrew Fletcher, Annika Whittle, David Bowen. 2010. Epidemiology and Etiology of Leukemias. , 17-28.
CrossRef8
P Armand, H T Kim, E Mayer, C S Cutler, V T Ho, J Koreth, E P Alyea, J H Antin, R J Soiffer. (2010) Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplantation 45:11, 1611-1617
CrossRef9
Pavani Chalasani, Leona Downey, Alison T. Stopeck. (2010) Caring for the Breast Cancer Survivor: A Guide for Primary Care Physicians. The American Journal of Medicine 123:6, 489-495
CrossRef10
Francesco Lo-Coco, Tamer M Fouad, Safaa M Ramadan. (2010) Acute leukemia in women. Women's Health 6:2, 239-249
CrossRef11
Soley Bayraktar, Maricer P. Escalón. (2010) Secondary hematological malignancies following breast cancer treatment. Oncology Reviews 4:1, 51-59
CrossRef12
HARUYO IWADATE, HIROKO KOBAYASHI, KIORI YANO, HIROSHI WATANABE, KAZUHIKO IKEDA, KAZUEI OGAWA, HIROMASA OHIRA. (2010) THERAPY-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING CYCLOPHOSPHAMIDE PULSE AND/OR METHOTREXATE THERAPY IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS. FUKUSHIMA JOURNAL OF MEDICAL SCIENCE 56:2, 121-127
CrossRef13
Jason D. Wright, Caryn M. St. Clair, Israel Deutsch, William M. Burke, Prakash Gorrochurn, Xuming Sun, Thomas J. Herzog. (2010) Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. CancerNA-NA
CrossRef14
Andrea K. Ng, Lisa B. Kenney, Ethel S. Gilbert, Lois B. Travis. (2010) Secondary Malignancies Across the Age Spectrum. Seminars in Radiation Oncology 20:1, 67-78
CrossRef15
Carolyn A. Felix. (2009) A safer regimen for high-risk neuroblastoma. Pediatric Blood & Cancer 53:1, 3-6
CrossRef16
Nakhle S. Saba, Semaan G. Kosseifi, Edris A. Charaf, Ahmad N. Hammad. (2008) Adalimumab-Induced Acute Myelogenic Leukemia. Southern Medical Journal 101:12, 1261-1262
CrossRef17
Aruna Padmanabhan, Julie A. Baker, Gary Zirpoli, Sheila N.J. Sait, Laurie A. Ford, Kirsten B. Moysich, Maria R. Baer. (2008) Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: Increased frequency of other cancers and of cancers in multiple family members. Leukemia Research 32:12, 1820-1823
CrossRef18
Lucy A. Godley, Richard A. Larson. (2008) Therapy-Related Myeloid Leukemia. Seminars in Oncology 35:4, 418-429
CrossRef19
M T Andersen, M K Andersen, D H Christiansen, J Pedersen-Bjergaard. (2008) NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 22:5, 951-955
CrossRef20
Andrea K. Ng, Lois B. Travis. (2008) Second Primary Cancers: An Overview. Hematology/Oncology Clinics of North America 22:2, 271-289
CrossRef21
Arwa Abdelhameed, Gregory R. Pond, Nicholas Mitsakakis, Joseph Brandwein, Kathy Chun, Vikas Gupta, Suzanne Kamel-Reid, Jeffrey H. Lipton, Mark D. Minden, Aaron Schimmer, Andre Schuh, Karen Yee, Hans A. Messner. (2008) Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer 112:7, 1513-1521
CrossRef22
Helena M. Verkooijen, Gerald Fioretta, Elisabetta Rapiti, Georges Vlastos, Isabelle Neyroud-Caspar, Pierre O. Chappuis, Christine Bouchardy. (2008) Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: Results from a population-based study. International Journal of Cancer 122:5, 1114-1117
CrossRef23
James P. Smith, Eric G. Neilson. 2008. Treatment of Acute Interstitial Nephritis. , 313-319.
CrossRef24
Vicent Guillem, Mar Tormo. (2008) Influence of DNA damage and repair upon the risk of treatment related leukemia. Leukemia & Lymphoma 49:2, 204-217
CrossRef25
Regan A. Howard, Ethel S. Gilbert, Bingshu E. Chen, Per Hall, Hans Storm, Eero Pukkala, Froydis Langmark, Magnus Kaijser, Michael Andersson, Heikki Joensuu, Sophie D. Fossa, Lois B. Travis. (2007) Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Research and Treatment 105:3, 359-368
CrossRef26
Stuart C. Finch. (2007) Radiation-induced leukemia: Lessons from history. Best Practice & Research Clinical Haematology 20:1, 109-118
CrossRef27
Val??rie Martinez, Olivier Mir, Julien D??mont, Didier Bouscary, Fran??ois Goldwasser. (2007) Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. Anti-Cancer Drugs 18:2, 233-235
CrossRef28
Rima F. Jubran, Judith G. Villablanca, Anna T. Meadows. 2007. Chemotherapy for retinoblastoma: an overview. , 449-453.
CrossRef29
Ian H. Gabriel, Saad H. Abdalla, Sarah Ryley, Barbara J. Bain. (2007) Case 34: Acute leukemia in a patient with a previous history of breast cancer. Leukemia & Lymphoma 48:2, 403-405
CrossRef30
L. B. Travis. (2007) Evaluation of the Risk of Therapy-Associated Complications in Survivors of Hodgkin Lymphoma. Hematology 2007:1, 192-196
CrossRef31
R. Renella, H.M. Verkooijen, G. Fioretta, G. Vlastos, J. Kurtz, A.P. Sappino, P. Schäfer, I. Neyroud-Caspar, C. Bouchardy. (2006) Increased risk of acute myeloid leukaemia after treatment for breast cancer. The Breast 15:5, 614-619
CrossRef32
Laura Orlando, Anna Cardillo, Andrea Rocca, Alessandra Balduzzi, Raffaella Ghisini, Giulia Peruzzotti, Aron Goldhirsch, Claudia D??Alessandro, Saverio Cinieri, Lorenzo Preda, Marco Colleoni. (2006) Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs 17:8, 961-967
CrossRef33
Guo-Pei Yu, Stimson P. Schantz, Alfred I. Neugut, Zuo-Feng Zhang. (2006) Incidences and Trends of Second Cancers in Female Breast Cancer Patients: A Fixed Inception Cohort-based Analysis (United States). Cancer Causes & Control 17:4, 411-420
CrossRef34
David T. Bowen. (2006) Etiology of Acute Myeloid Leukemia in the Elderly. Seminars in Hematology 43:2, 82-88
CrossRef35
Shilpi Narula, Sindhu Cherian, Stephen Schuster, Ara A. Chalian, Andrea J. Apter. (2006) A 65-year-old woman with intractable nasal congestion. Annals of Allergy, Asthma & Immunology 96:2, 281-285
CrossRef36
Richard C. Chao, Urszula Pyzel, Jane Fridlyand, Yien-Ming Kuo, Lewis Teel, Jennifer Haaga, Alexander Borowsky, Andrew Horvai, Scott C. Kogan, Jeannette Bonifas, Bing Huey, Tyler E. Jacks, Donna G. Albertson, Kevin M. Shannon. (2005) Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell 8:4, 337-348
CrossRef37
Elena B. Elkin, Milton C. Weinstein, Karen M. Kuntz, Craig A. Bunnell, Jane C. Weeks. (2005) Adjuvant Ovarian Suppression Versus Chemotherapy for Premenopausal, Hormone-responsive Breast Cancer: Quality of Life and Efficacy Tradeoffs. Breast Cancer Research and Treatment 93:1, 25-34
CrossRef38
YUICHI OTSUKA, TOSHIRO KONISHI, SATOSHI NARA, KAORU FURUSHIMA, KENTARO NAKAJIMA, HIROSHI SHIMADA. (2005) Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer. Journal of Gastroenterology and Hepatology 20:9, 1318-1321
CrossRef39
Alessandra Balduzzi, Monica Castiglione-Gertsch. (2005) Leukemia risk after adjuvant treatment of early breast cancer. Women's Health 1:1, 73-85
CrossRef40
Bruce A. Chabner, Thomas G. Roberts. (2005) Timeline: Chemotherapy and the war on cancer. Nature Reviews Cancer 5:1, 65-72
CrossRef41
Myung Joon Park, Yeon Hee Park, Heui June Ahn, Won Choi, Kwang Hyun Paik, Jung Min Kim, Yoon Hwan Chang, Baek-Yeol Ryoo, Sung Hyun Yang. (2005) Secondary hematological malignancies after breast cancer chemotherapy. Leukemia & Lymphoma 46:8, 1183-1188
CrossRef42
M. Jane Teta, Nga L. Tran, Pamela J. Mink, Leila M. Barraj. (2004) Validity of Using Background Leukemia Incidence Rates with Cohort Mortality-Based Potency Estimates to Calculate Excess Lifetime Risk. Human and Ecological Risk Assessment: An International Journal 10:5, 923-938
CrossRef43
Nuhad K. Ibrahim. (2004) Leukemogenic effect of chemotherapy in patients with breast carcinoma. Cancer 101:7, 1479-1481
CrossRef44
Michela Casanova, Andrea Ferrari, Gianni Bisogno, Johannes H. M. Merks, Gian Luca De Salvo, Cristina Meazza, Katia Tettoni, Massimo Provenzi, Ida Mazzarino, Modesto Carli. (2004) Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas. Cancer 101:7, 1664-1671
CrossRef45
Henry G. Kaplan, Judith A. Malmgren, Mary Atwood. (2004) Leukemia incidence following primary breast carcinoma treatment. Cancer 101:7, 1529-1536
CrossRef46
R Roychoudhuri, H Evans, D Robinson, H Møller. (2004) Radiation-induced malignancies following radiotherapy for breast cancer. British Journal of Cancer
CrossRef47
Helena Earl, Mahesh Iddawela. (2004) Epirubicin as adjuvant therapy in breast cancer. Expert Review of Anticancer Therapy 4:2, 189-195
CrossRef48
M. Ohara, M. Kobayashi, H. Fujiwara, S. Kitajima, C. Mitsuoka, H. Watanabe. (2004) Blue light inhibits melanin synthesis in B16 melanoma 4A5 cells and skin pigmentation induced by ultraviolet B in guinea-pigs. Photodermatology, Photoimmunology and Photomedicine 20:2, 86-92
CrossRef49
Sister Mary Andrew Matesich, Charles L Shapiro. (2003) Second cancers after breast cancer treatment. Seminars in Oncology 30:6, 740-748
CrossRef50
C. Emmanouilides, M. Territo, H. Menco, R. Patel, P. Rosen. (2003) Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. Hematological Oncology 21:3, 99-108
CrossRef51
Shonda Davis-Perry, Enrique Hernandez, Karen L. Houck, Rachel Shank. (2003) Melphalan for the Treatment of Patients With Recurrent Epithelial Ovarian Cancer. American Journal of Clinical Oncology 26:4, 429-433
CrossRef52
Elaine Ron. (2003) CANCER RISKS FROM MEDICAL RADIATION. Health Physics 85:1, 47-59
CrossRef53
Evangelos Briasoulis, Evangelia Tzouvara, Stavroula Tsiara, Giorgos Vartholomatos, Pericles Tsekeris, Konstantinos Bourantas. (2003) Biphenotypic Acute Leukemia Following Intensive Adjuvant Chemotherapy for Breast Cancer: Case Report and Review of the Literature. The Breast Journal 9:3, 241-245
CrossRef54
Masayuki Ohara, Yuzo Kawashima, Shunichi Kitajima, Chihomi Mitsuoka, Hiromitsu Watanabe. (2003) Blue light inhibits the growth of skin tumors in the v-Ha-ras transgenic mouse. Cancer Science 94:2, 205-209
CrossRef55
(2002) Breast Cancer and Splenic Non-Hodgkin's Lymphoma, a Rare Occurrence. The Breast Journal 8:6, 400-401
CrossRef56
Christopher B. Weldon, Bernard M. Jaffe, Marc J. Kahn. (2002) Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: An underemphasized clinical problem. Annals of Surgical Oncology 9:8, 738-744
CrossRef57
Clifford Hudis. (2002) Breast Cancer and Leukemia: The forest for the trees?. Annals of Surgical Oncology 9:8, 717-718
CrossRef58
TANJA PEJOVIC, PETER E. SCHWARTZ. (2002) Leukemias. Clinical Obstetrics and Gynecology 45:3, 866-878
CrossRef59
Masayuki Ohara, Yuzo Kawashima, Osamu Katoh, Hiromitsu Watanabe. (2002) Blue Light Inhibits the Growth of B16 Melanoma Cells. Cancer Science 93:5, 551-558
CrossRef60
Helen K Chew. (2002) Medical Management of Breast Cancer: Today and Tomorrow. Cancer Biotherapy & Radiopharmaceuticals 17:2, 137-149
CrossRef61
Marilyn L. Slovak, Victoria Bedell, Leslie Popplewell, Daniel A. Arber, Claudia Schoch, Rosalyn Slater. (2002) 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: Report from an International Workshop. Genes, Chromosomes and Cancer 33:4, 379-394
CrossRef62
Gareth J. Morgan, Martyn T. Smith. (2002) Metabolic Enzyme Polymorphisms and Susceptibility to Acute Leukemia in Adults. American Journal of PharmacoGenomics 2:2, 79-92
CrossRef63
Philip Rubin, Antje Wefer, Hedvig Hricak, Louis S. Constine, Jacqueline Williams, Frank T. Slovick. 2002. Late Effects. , 895-939.
CrossRef64
Paul D. Brown, James A. Bonner, Robert L. Foote, Stephen Frytak, Randolph S. Marks, Ronald L. Richardson, Edward T. Creagan. (2001) Long-term Results of a Phase I/II Study of High-Dose Thoracic Radiotherapy With Concomitant Cisplatin and Etoposide in Limited Stage Small-Cell Lung Cancer. American Journal of Clinical Oncology 24:6, 556-561
CrossRef65
A. H. Partridge, H. J. Burstein, E. P. Winer. (2001) Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. JNCI Monographs 2001:30, 135-142
CrossRef66
(2001) National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. JNCI Monographs 2001:30, 5-15
CrossRef67
Julian W Adlard, David J Dodwell. (2001) Optimum anthracycline-based chemotherapy for early breast cancer. The Lancet Oncology 2:8, 469-474
CrossRef68
Jenny Huang, Willian J. Mackillop. (2001) Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92:1, 172-180
CrossRef69
Jenny Huang, Willian J. Mackillop. (2001) Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92:1, 172-180
CrossRef70
Jenny Huang, Willian J. Mackillop. (2001) Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92:1, 172-180
CrossRef71
Jenny Huang, Willian J. Mackillop. (2001) Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92:1, 172-180
CrossRef72
Jenny Huang, Willian J. Mackillop. (2001) Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92:1, 172-180
CrossRef73
Jenny Huang, Willian J. Mackillop. (2001) Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92:1, 172-180
CrossRef74
Wood, Alastair J.J., , Shapiro, Charles L., Recht, Abram, . (2001) Side Effects of Adjuvant Treatment of Breast Cancer. New England Journal of Medicine 344:26, 1997-2008
Full Text75
Mark P Little. (2001) Cancer after exposure to radiation in the course of treatment for benign and malignant disease. The Lancet Oncology 2:4, 212-220
CrossRef76
Eldad J. Dann, Jacob M. Rowe. (2001) Biology and therapy of secondary leukaemias. Best Practice & Research Clinical Haematology 14:1, 119-137
CrossRef77
Catherine Wheeler, Anwar Khurshid, Joseph Ibrahim, Anthony Elias, Peter Mauch, Kenneth Ault, Joseph Antin. (2001) Incidence of Post Transplant Myelodysplasia/Acute Leukemia in Non-Hodgkin's Lymphoma Patients Compared with Hodgkin's Disease Patients Undergoing Autologous Transplantation Following Cyclophosphamide, Carmustine, and Etoposide (CBV). Leukemia & Lymphoma 40:5-6, 499-509
CrossRef78
Giuseppe Leone, Maria Teresa Voso, Simona Sica, Roberta Morosetti, Livio Pagano. (2001) Therapy Related Leukemias: Susceptibility, Prevention and Treatment. Leukemia & Lymphoma 41:3-4, 255-276
CrossRef79
Farhang Rabbani, Victor E Reuter, Jared Katz, Paul Russo. (2000) Second primary malignancies associated with renal cell carcinoma: influence of histologic type. Urology 56:3, 399-403
CrossRef80
S Mussari, M Amichetti, L Tomio. (2000) CASE REPORTS: Quadruple cancer in a single patient: a report of four cases. European Journal of Surgical Oncology (EJSO) 26:6, 614-616
CrossRef81
Carlos Rodriguez-Galindo, Catherine A. Poquette, Neyssa M. Marina, David R. Head, Alvida Cain, William H. Meyer, Victor M. Santana, Alberto S. Pappo. (2000) Hematologic Abnormalities and Acute Myeloid Leukemia in Children and Adolescents Administered Intensified Chemotherapy for the Ewing Sarcoma Family of Tumors. Journal of Pediatric Hematology/Oncology 22:4, 321-329
CrossRef82
Benson, Kjell, Hartz, Arthur J., . (2000) A Comparison of Observational Studies and Randomized, Controlled Trials. New England Journal of Medicine 342:25, 1878-1886
Full Text83
M. Colleoni, L. Orlando, F. Nole', A. Goldhirsch. (2000) Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality. The Breast 9:3, 134-138
CrossRef84
Carole Rubino, Florent de Vathaire, Ibrahima Diallo, Akhtar Shamsaldin, Monique G Lê. (2000) Increased risk of second cancers following breast cancer: Role of the initial treatment. Breast Cancer Research and Treatment 61:3, 183-195
CrossRef85
G. Hortobagyi. (2000) Adjuvant Therapy for Breast Cancer. Annual Review of Medicine 51:1, 377-392
CrossRef86
Jan G. Hengstler, Andreas Bockisch, Juergen Fuchs, Werner Grimm, R. Görges, Barbara Oesch-Bartlomowicz, Arndt-Oliver Zapf, Kerstin Lade, Berno Tanner, Elke Teichmann, Manfred Thelen, Susanne Gebhard, Franz Oesch. (2000) Induction of DNA Single-Strand Breaks by 131I and 99mTc in Human Mononuclear Blood Cells In Vitro and Extrapolation to the In Vivo Situation. Radiation Research 153:5, 512
CrossRef87
Francisco J. Esteva, Gabriel N. Hortobagyi. (1999) ADJUVANT SYSTEMIC THERAPY FOR PRIMARY BREAST CANCER. Surgical Clinics of North America 79:5, 1075-1090
CrossRef88
Hilde Engels, Hans G. Menzel, Pascal Pihet, André Wambersie. (1999) Risk assessment for cancer induction after low- and high-LET therapeutic irradiation. Strahlentherapie und Onkologie 175:S2, 47-51
CrossRef89
Travis, Lois B., Holowaty, Eric J., Bergfeldt, Kjell, Lynch, Charles F., Kohler, Betsy A., Wiklund, Tom, Curtis, Rochelle E., Hall, Per, Andersson, Michael, Pukkala, Eero, Sturgeon, Jeremy, Storm, Hans, Clarke, E. Aileen, Boice, John D. Jr., Gospodarowicz, Mary, Stovall, Marilyn, . (1999) Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer. New England Journal of Medicine 340:5, 351-357
Full Text90
FARHANG RABBANI, GREGORY GRIMALDI, PAUL RUSSO. (1998) MULTIPLE PRIMARY MALIGNANCIES IN RENAL CELL CARCINOMA. The Journal of Urology 160:4, 1255-1259
CrossRef91
Susan Goodin, Robert S. DiPaola. (1998) Strategies for using cytoprotective agents to improve outcomes associated with cancer chemotherapy. Disease Management and Clinical Outcomes 1:5, 155-160
CrossRef92
M. Back, G. Delaney, J. Denham, P. Graham, C. Hamilton, G. Morgan, P. O'Brien, P. Yuile. (1998) HOW SHOULD WE INTRODUCE HIGH-DOSE CHEMOTHERAPEUTIC STRATEGIES INTO THE ADJUVANT MANAGEMENT OF HIGH-RISK BREAST CANCER IN AUSTRALASIA?. ANZ Journal of Surgery 68:1, 10-15
CrossRef93
Hillard M. Lazarus. (1998) Clinical Trial: Hematopoietic Progenitor Cell Transplantation in Breast Cancer: Current Status and Future Directions. Cancer Investigation 16:2, 102-126
CrossRef94
Joanne L. Blum, Stephen E. Jones, Joseph W. Fay, Neil Senzer, Robert G. Mennel. (1997) Guidelines for systemic therapy of early stage breast cancer. Breast Cancer Research and Treatment 43:3, 259-276
CrossRef95
Michael J. Thirman, Richard A. Larson. (1996) THERAPY-RELATED MYELOID LEUKEMIA. Hematology/Oncology Clinics of North America 10:2, 293-320
CrossRef96
Alfred I. Neugut, Todd Murray, Jason Santos, Howard Amols, Mary K. Hayes, John T. Flannery, Eliezer Robinson. (1994) Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73:6, 1615-1620
CrossRef97
N.J. Philpott, D.H. Bevan, E.C. Gordon-Smith. (1993) Secondary leukaemia after MMM combined modality therapy for breast carcinoma. The Lancet 341:8855, 1289
CrossRef98
M P Little. (1993) Risks of radiation-induced cancer at high doses and dose rates. Journal of Radiological Protection 13:1, 3-25
CrossRef99
Martin R. Chasen, Geoffrey Falkson. (1993) Leukemia after Chemotherapy for Cancer. Cancer Biotherapy 8:2, 115-122
CrossRef100
Harris, Jay R., Lippman, Marc E., Veronesi, Umberto, Willett, Walter, . (1992) Breast Cancer. New England Journal of Medicine 327:7, 473-480
Full Text101
Henderson, I. Craig, . (1992) Breast Cancer Therapy — The Price of Success. New England Journal of Medicine 326:26, 1774-1775
Full Text
